Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) Income from Continuing Operations (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Income from Continuing Operations for 3 consecutive years, with 34166000.0 as the latest value for Q1 2026.

  • Quarterly Income from Continuing Operations fell 57.02% to 34166000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 135626000.0 through Jan 2026, down 1310.86% year-over-year, with the annual reading at 105552000.0 for FY2025, 463.06% down from the prior year.
  • Income from Continuing Operations for Q1 2026 was 34166000.0 at Kestra Medical Technologies, down from 32785000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 53090000.0 in Q2 2024, with the low at 42849000.0 in Q2 2025.
  • Average Income from Continuing Operations over 3 years is 18539777.78, with a median of 21759000.0 recorded in 2025.
  • Peak annual rise in Income from Continuing Operations hit 0.65% in 2025, while the deepest fall reached 180.71% in 2025.
  • Over 3 years, Income from Continuing Operations stood at 20621000.0 in 2024, then plummeted by 58.99% to 32785000.0 in 2025, then fell by 4.21% to 34166000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 34166000.0, 32785000.0, and 25826000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.